Introduction
Most sporadic solid tumors require several mutational genetic events prior to acquisition of a malignant phenotype and development of neoplasia. Age-specific incidence data in head and neck squamous cell carcinomas (HNSCC), suggests that these cancers arise after seven to 10 mutations, deletions, or other genetic events (Renan, 1993) . This estimation is supported by the number of tumor specific losses and amplifications documented by comparative genomic hybridization and loss of heterozygosity studies (Grati et al., 2000) . These genetic events are supposed to be acquired in a 10 to 25-year latency period. During this time, exposure to carcinogens, mainly tobacco and alcohol, is believed to be the predominant cause of genetic alterations during HNSCC progression (Vokes et al., 1993) . These genetic abnormalities may involve genes important to cell cycle control, apoptosis, angiogenesis, cell adhesion, transmembrane signaling, DNA repair, and genomic stability. Changes in DNA copy number involving these genes are one of the most important mechanisms leading to deregulated gene expression and neoplastic transformation (Loeb and Loeb, 2000) .
Gene quantification tests are very important for the molecular genetic characterization of cancers caused by either amplification or deletion of a specific DNA region harboring specific genes. Several molecular alterations have been described that are thought to play a role in HNSCC development and progression, including the MYC, RAS, ERBB2, BCL2, INT2 and HST1 oncogenes, and TP53, TP16, CDKN2, and BRCA2 tumor suppressor genes (Quon et al., 2001) . However, the genetic changes underlying the malignant cellular behavior and their correlation with clinical and histopathological parameters are still not completely understood.
Loss of heterozygosity (LOH) studies are useful as a preliminary tool to narrow specific regions, which may contain tumor suppressor genes that can play a role in cancer development or progression. Although haplotype analysis is a powerful method, evidence for deletion of a gene involved in the genesis of a genetic disease may be indirect, since loss must usually be inferred based on the analysis of flanking markers rather than direct study of the gene itself.
Several chromosomal arms are reported to be involved in LOH in different types of tumors. LOH has been frequently detected on the long arm of chromosome 22 in a variety of human solid tumors, especially in tumor cells of embryonic-neural-crest origin, including meningiomas (Ueki et al., 1999) , astrocytomas (Oskam et al., 2000) , schwanomas (Twist et al., 1995) and pheochromocytomas (Shin et al., 1993) , but also in thyroid carcinomas (Kitamura et al., 2000) , colorectal cancers (Castells et al., 1999) , ovarian carcinomas (Englefield et al., 1994) , renal rhabdoid tumors (Biegel et al., 2000) , gastrointestinal metastatic cancer (Kim et al., 2000) , breast cancer (Bryan et al., 2000) and head and neck squamous cell carcinomas from different anatomic sites (Bockmu¨hl et al., 1998) . In particular, LOH restricted to the 22q13.31 region has been detected in oral cavity carcinomas (Miyakawa et al., 1998; Poli-Frederico et al., 2000) .
The measurement of gene copy number by real time PCR using DNA or RNA in gene expression studies has been reported in the literature for human tumors, including breast cancer (Bie`che et al., 1998; Lehmann et al., 2000; Mitas et al., 2001) , follicular lymphoma (Goff et al., 2000) , gastric cancer (Nakanishi et al., 2000) , prostate cancer (Helenius et al., 2001) , and Ewings tumor (Peter et al., 2001) . In head and neck carcinomas, this new technology has been applied mainly for detection of Epstein-Barr virus in nasopharyngeal cancers (Lo et al., 2000) , and in lymph nodes from squamous cell carcinomas (Cortesina et al., 2000) . To our knowledge, there are no studies thus far quantitating specific genes on 22q in oral cavity carcinomas and the correlation with the clinical and histopathological parameters and survival.
In the present study, we applied quantitative fluorescent real-time PCR analysis in 40 primary oral squamous cell carcinomas to determine the relative DNA copy number of four genes and two microsatellite markers mapping to chromosome 22 (Table 2 ). The region 22q13 was selected for this molecular investigation based on previous CGH and LOH (Reis et al., 2001 ) results reported by our group. 
Results
Forty samples from oral cavity carcinomas and the normal adjacent tissues were investigated for alterations in DNA copy number on 22q13.1 -13.33. The mean age of patients was 57.8 (range 22 -86) and the male : female ratio was 4 : 1; most of them were smokers and drinkers (Table 1 ). The mean followup was 15.8 months. The follow-up period was variable between 2 and 48 months. During this interval 11 patients died and the calculated median for survival was 10 months (range 4 -27 months). Three patients (7.5%) were lost to follow-up. These patients were censored as survivors in these statistical calculations.
The efficiency of primers to detect disomic quantities of the target genes was validated using human genomic DNA standards. The presence of gene loss or amplification in the oral cavity tumor samples was first validated by determination of the mean value ratios for all cell lines and normal controls for all primers after eight repetitions. These values did not show statistically significant differences between the ratios in each sample for all genes tested. The values obtained for the controls were the following: for the normal placental DNA (disomic), the interval ranged from 0.9959 to 1.1237, with a confidence interval of 0.06391; for the cell line KG-1a (#CCL 246-1) (monosomic), the interval ranged from 0.5219 to 0.6888, with a confidence interval of 0.08348 and for the trisomic cell line Hs 578T (#HTB 126), the interval determined ranged from 1.4580 to 1.7295, with a confidence interval of 0.13571.
Normal adjacent tissues were also evaluated for gene dosage alterations for all primers. The quantitative results for the normal adjacent tissues revealed normal patterns of amplification for all primers.
Quantification results in the tumor samples showed losses for the microsatellite marker D22S274 and for the gene NADH cytochrome-b5 reductase. DIA1, in 10 out of 40 cases (25%). From these cases, 7 out of 10 presented losses for both regions. Statistically significant correlations were verified in patients presenting with a deletion of the sequence D22S274 and with a clinical stage T3 -T4 (P=0.025), for family history of cancer (P=0.001) and death (P=0.021). Loss involving the DIA1 gene revealed statistically significant correlations with the following parameters: family history of cancer (P50.001), alcohol consumption (P=0.026) and death (P=0.002) ( Table 3) . A significant decrease in survival probability (P=0.0018) was observed for patients presenting with DIA1 gene losses ( Table 4 ). The overall survival of patients was 54.7% over 5 years. The hazard ratio or relative risk (RR) to variable DIA1 was RR=5.3 (95% CI: 1.6 -17.5) and for T clinical stage adjusted RR=4.8 (95% CI: 1.4 -15.9). These values indicate that DIA1 is an independent prognostic factor. These values also demonstrate that the presence of DIA1 gene deletion increases the risk of death in a five-range order in comparison with patients who did not present DIA1 gene deletion.
In our samples, 10 out of 10 and 9 out of 10 patients presenting with relative copy number loss of the DIA1 gene and the D22S274 marker, respectively, had a family history of cancer. Two cases had losses for all genes.
Amplification plots obtained for the genes GAPDH (dilutions of normal placental DNA, normal DNA and tumor samples) and DIA1 (tumor samples) are shown in Figure 1 .
We performed FISH analysis of four cases in this series (5, 6, 7, 18 ) that showed relative copy number losses for the DIA1 gene by quantitative PCR. Representative metaphase and interphase FISH images are depicted in Figure 1e . In all cases, FISH analysis showed most cells to have two copies of centromere 22 signals (97%) and a smaller percentage of cells to have three copies. Examination of the DIA1 gene copy number by interphase FISH demonstrated that the majority of cells had predominantly two DIA1 gene copies, with the greatest frequency being 79% of cells. DIA1 gene loss was detected at a frequency that ranged between 15 and 23% of cells in the four cases. Losses of two copies of DIA1 gene were detected in case 18 in 18% of cells. 
Discussion DNA copy number alterations, including deletions or duplications of genes or specific genomic regions can lead to under or overexpression of these sequences and can be responsible for disease phenotype (Ruiz-Ponte et al., 2000) . Gene copy number analysis by quantitative real time PCR can be targeted directly to a subregion of a gene or microsatellite marker sequence of interest and does not depend on the availability of informative flanking markers or parental DNA.
In the present study, we used quantitative real time PCR to detect losses involving genes mapped to the 22q13.1 -13.33 region in human oral cavity cancer.
Quantitative results revealed losses involving the microsatellite marker D22S274, mapping to 22q13.31 in 10 out of 40 cases (25%), and the DIA1 gene, located at 22q13.2 -13.31 in 10 out of 40 cases (25%).
Seven of these 10 cases showed relative copy number loss for both sequences. Statistical analysis revealed a significant correlation between the presence of relative copy number loss in these two sequences, family history of cancer and death. In our sample, 10 out of 10 and 9 out of 10 patients who have loss of DIA1 and D22S274, respectively had a family history of cancer. Three cases showed a history of colon cancer in siblings and losses in the DIA1 gene and in the marker D22S274. In addition, two cases presented with a history of head and neck cancer in siblings and loss of these two sequences.
Recently, Castells et al. (1999) evaluated the incidence of LOH on 22q in colorectal cancer. The authors detected a minimal deleted region in 22q13.33 in 11 out of 50 (22%) of the informative cases. The D22S274 locus was preferentially involved in these losses. This interesting coincident occurrence of LOH in a variety of tumor types, associated with a history of cancer suggests that common sequences in this region may be involved, a potential finding in concert with observations of other tumor suppressor genes, such as TP53 and TP16.
From the 11 patients who died in a follow-up period of up to 48 months, six presented with metastasis. Three of these cases revealed relative copy number loss for both the D22S274 marker and the DIA1 gene. Our analysis by quantitative PCR indicates that these sequences are present at a hemizygous level. Followup time varied between 4 and 20 months. Three patients presenting with a relative copy number loss for these two sequences, DIA1 and D22S274 are alive, in a follow-up time variable between 2 and 12 months.
Relative copy number loss of the marker D22S274 was correlated with disease stage in patients with T3 -T4 disease. Nine out of 10 patients with deletion in the Miyakawa et al. (1998) described loss of heterozygosity (LOH) involving this microsatellite marker in 11 out of 27 (40%) of informative cases from the oral cavity. However, the authors did not find any statistically significant correlation with the clinical and histopathological parameters of patients. In oral cavity tumor samples, we reported previously loss of heterozygosity for this microsatellite marker in 4 out of 27 (15%) of informative cases. There are two possible ways that can explain the different frequencies of LOH involving the marker D22S274, observed in our different reports, besides the experimental variation in the sensitivity of LOH and quantitative PCR methodologies. Firstly, this may be due to trace contamination of the template with DNA from normal cells and this could have led to over-representation of heterozygosity in subsequent PCR amplification steps.
It is well established that allelotyping using microsatellite markers is prone to PCR biases. Secondly, and more interestingly, it is possible that more complex genomic rearrangements are taking place in this region of chromosome 22 in oral tumors.
We are unaware of other reports of oral cavity neoplasms concerning losses involving sequences mapping to the region 22q13.31 that also incorporate patient follow-up and survival data of patients.
The prognostic value of losses in the overall survival was statistically assessed by the Log-rank test. We detected a decrease in the probability of survival in presence of relative copy number loss involving the microsatellite marker D22S274 and the DIA1 gene. Although D22S274 deletion had shown marginal significance (P=0.058), DIA1 gene deletion was statistically significant (P=0.0018) ( Table 4) .
DIA1 gene deletion has also showed a statistical significant correlation (P=0.026) with alcohol Figure 1 (a) Standard curve for the GAPD gene plotting log of starting copy number versus threshold cycle Ct. The black dots represent the data for standard samples and the red dots the data for unknown genomic DNA from samples and controls plotted in triplicate. Amplification plots for reactions with GAPDH gene for dilutions of normal placental DNA (b); tumor samples, cell lines control, placental DNA, and non-template control showing no differences between all samples (c), and for the DIA1 gene showing significant differences in the amount of amplified product in one tumor sample (d). Cycle number is plotted versus change in normalized reporter signal (DRn). DRn represents the normalized reporter signal (Rn) minus the baseline signal established in the first 15 PCR cycles. DRn increases in the PCR as gene copy number increases until the reaction reaches a plateau. (e) Representative metaphase and interphase nuclei FISH images using BAC RPI22E13 probe for the DIA1 gene (green, indicated by an arrow) and control probe pEFZ31 mapped on 22q12.1 (red). Loss for the chromosome 22 including DIA1 gene was seen in the tumor sample from case 18. Loss for the DIA1 gene was detected in case 7 consumption. From the patients showing relative copy number loss for this gene, 9 out of 10 had history of heavy consumption of alcohol. Alcohol consumption is now being recognized as an important etiological factor in the development of oral cancer (Wight and Ogden, 1998) . Despite this, the mechanism by which alcohol may exert an influence in the oral mucosa is not completely understood.
The DIA1 gene, located in 22q13.2 -13.31 and the marker D22S274, are both mapped to 22q13.31, and are spaced 2.5 cM apart. The concomitant loss of both sequences suggests the involvement of a large region of deletion associated with prognostic factors in tongue and floor of the mouth carcinomas. This region contains CpG islands, poly A sequences, and several ESTs (www.sanger.ac.uk/HGPChr22), that indicate that this region may contain a variety of genes.
The other genes investigated included the gene ECGF1 (endothelial cell growth factor 1), mapped to 22q13.33, which codifies a protein that participates in angiogenesis in vivo (Hagiwara et al., 1991) ; BIK, which synthesizes a protein that interacts with other essential cellular proteins and induces apoptosis (Boyd et al., 1995) ; and PDGFB, a potent mitogen involved in the cellular transformation process (Josephs et al., 1984) . Two common cases presented relative copy number loss for all these genes. From these, only one presented with a history of metastasis and died within a period of 10 months. The detection of losses for all sequences investigated on chromosome 22q probably reflects the occurrence of one copy of chromosome 22 or a large deletion involving this region.
In this study, FISH analysis was applied to validate/ confirm DIA1 gene relative copy number loss in comparison to the centromeric 22 region in four cases of oral cavity tumors that showed relative copy number loss by quantitative PCR. This technique is commonly applied as an auxiliary in microdeletion analysis, identification of marker chromosomes, characterization of structural rearrangements, ploidy analysis in prenatal diagnosis and in studies of gene loss or amplification (Blancato, 1999) .
Oral cancers can present with a near-triploid or neartetraploid karyotype, as well as loss of several chromosomes. Losses of the DIA1 gene were observed in all cases at a low frequency. In addition, case 18 revealed loss of two copies of DIA1 gene by FISH. This finding is in agreement with the quantitative PCR results, revealing losses for all markers tested. These results validate the quantitative analysis, revealing the absence of this gene sequence in a portion of cells in this case of oral cavity tumor.
An exact quantitative analysis of gene copy number alterations in disease will allow us to identify areas of the genome that may be important for tumor survival. Determination of gene deletion in various cancers can be used as a marker of progression, for early diagnosis of cancer, staging, prognostication and choice of treatment. This study provides more compelling evidence for the potential involvement of putative tumor suppressor genes on 22q13 in oral carcinogenesis.
Materials and methods

Samples and DNA extraction
Forty samples of primary oral carcinomas restricted to tongue (30 cases) and floor of the mouth (10 cases) were surgically removed and obtained from Hospital A.C. Camargo de Sa˜o Paulo and Hospital das Clı´nicas, UNESP, Botucatu, SP, Brazil (Table 1) . Informed consent was obtained from all the patients prior to sampling. This work was performed with the authorization of the Brazilian Federal Ethics Committee-CONEP 813/2000.
The medical records of all patients were examined by a pathologist to obtain the clinical and histopathological informations. The family history of cancer considered firstand second-degree relatives with cancer as informative. Where possible all assessments were based on the documented medical records as evidence of cancer. For some families a history of cancer was ascertained by a cancer geneticist interviewing patients and relatives.
None of the patients had undergone radiotherapy or chemotherapy before surgery. Immediately after surgery, the tumor samples were frozen at 7808C until extraction of high molecular weight DNA could be performed. Each sample was histopathologically evaluated to ensure the presence of at least 80% of tumor cells. Histopathological classification was performed according to the WHO International Classification of Diseases for Oncology (1990) . The clinical staging was determined by the TNM Staging System (AJCC, 1998) .
A peripheral blood sample and from the normal adjacent tissue was collected from all patients; the latter was histopathologically analysed to confirm the presence of only normal cells.
DNA was prepared using standard methodology with proteinase K, extracted by phenol-chloroform, and precipitated with 100% ethanol.
DNA samples were stored at 7208C.
Controls
The cell lines KG-1a (#CCL 246-1) (derived from chronic myeloid leukemia), containing monosomy of chromosome 22 and Hs 578T (#HTB 126) (derived from human breast cancer) containing trisomy of chromosome 22 were obtained from the American Type Culture Collection (ATCC) (Rockville, MD, USA). Cell lines were cultured according to the recommendations from ATCC to confirm their karyotypes. A human normal placental DNA was used as a standard and as a normal amplification control, in addition to the DNA from the normal adjacent tissues from all tumor samples.
Quantitative PCR using the real time system
We used the ABI Prism 7700 Sequence Detection System (PE Applied Biosystems) for real time detection. This system operates using a thermal cycler and a laser that is directed via fiber optics to each of 96 sample wells. This study was performed with the SYBR Green I dye, a highly specific double-stranded DNA binding dye that allows the detection of product accumulation during each PCR cycle (Simpson et al., 2000) . The fluorescence emission from each sample is collected by a charge-coupled device-camera and the data are automatically analysed. Quantitation of the amount of target in unknown samples is accomplished by measuring the Ct using the standard curve. The fractional cycle number (Ct) at which the amount of amplified target reaches a fixed threshold is directly related to the amount of starting target. A higher starting copy number of the genomic DNA target will result in an earlier and significant increase in fluorescence. Quantitative data was analysed using the Sequence Detection System software (v. 1.7) (PE Applied Biosystems).
In addition, we have also quantified the housekeeping gene (GAPDH) as a control reference gene. GAPDH is mapped to 12p13 and it is adopted in several quantitative studies using DNA or RNA (Thellin et al., 1999) . This relative quantification is given by the ratio between the mean value of the target gene and the mean value of the GAPDH gene in each sample. This method normalizes the amount and the quality of genomic DNA (Bustin, 2000) .
Standard curve method
A relative standard curve was constructed for all primers with serial dilutions of human placental DNA (20, 10, 1, 0.1 ng/ ml). A standard curve for the housekeeping gene GAPDH is shown in Figure 1a . Each target gene was quantified in each assay using the standard curve in each experiment. Data from the standard curve with a correlation coefficient of less than 0.99 were not considered.
Genes and primers
Genes were selected according to their cytogenetic location on 22q13 and in instances where the functional protein product had been previously demonstrated to be associated with the neoplastic process. DNA sequences for each gene were selected from the international published database (www.ncbi.nlm.nih.gov/genebank). Primers were selected and designed for optimal hybridization kinetics using the Primer Express software (version 1.5) (PE Applied Biosystems, Foster City, CA, USA) ( Table 2) .
PCR amplification
Reaction mixtures contained 10 ng/ml of genomic DNA, 10 mM of each primer and 12.5 ml 2XSYBR Green PCR Master Mix (PE Applied Biosystems), which includes the SYBR Green I fluorescent dye, 0.5 units of AmpErase uracyl-N-glycosylase (UNG) enzyme, 1.25 units of Ampli-Taq Gold DNA polymerase, 200 mM dideoxinucleotides, and optimized buffer components. All primers were amplified using the same conditions. Thermal cycling conditions comprised of 508C for 2 min (this step is optimal for UNG enzyme activity), 958C for 10 min, and 35 cycles at 958C for 15 s followed by 608C for 1 min. Each assay included standard dilutions, cell line control DNA, human normal placental DNA and a nontemplate control. Experiments were repeated when a coefficient of variation higher than 5% was observed.
Fluorescence in situ hybridization (FISH)
A tissue fragment of four samples was processed after shortterm (5 -8 days) culture for cytogenetic analysis according to procedures previously described (Dracopoli, 2000) . Normal cytogenetic control slides were made from phytohemagglutinin-stimulated normal male lymphoblasts. Sequences BAC RPI222E13 (Genebank #Z93241) and pEFZ31 (D22S32) were used as probes. The DNA probe BAC RPI222E13 was labeled with biotin-14-dATP (Gibco BRL) and the probe pEFZ31 (D22S32), specific to the region 22q12.1 was labeled with digoxigenin-11-dUTP (Gibco BRL). Probe labeling, hybridization, suppression hybridization, detection, and fluorescence microscopy and microphotography were performed as previously described (Rogatto et al., 1999) . A minimum of 100 cells was evaluated in each cytogenetic sample for assessing the DIA1 gene frequencies of loss.
Statistical analysis
The data were analysed using the Fisher's exact test. Chisquare test and the Kaplan-Meier survival estimates. A logrank test was applied for comparison among survival curves. Tumors were grouped as T 1 and T 2 versus T 3 and T 4 , as well as N 0 versus N 1 , N 2 and N 3 . Similarly, grade was analysed as grade I versus grades II and III. Statistical significance was defined as P50.05. The proportional hazard ratio or relative risk (RR) was obtained by Cox Regression analysis. Patient follow up data are presented in months, and comprised the interval between the date of surgery and patient's death or the last date of follow-up.
